NICE U-turn puts Janssen's Zytiga ahead of Sanofi's Jevtana in prostate cancer
This article was originally published in Scrip
Executive Summary
A revised patient access scheme and more information about the patients likely to benefit from Janssen Cilag's Zytiga (abiraterone) have persuaded NICE, the health technology appraisal body for England and Wales, to change its mind and recommend the drug for castration-resistant metastatic prostate cancer patients after one round of treatment with docetaxel.